Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
The Effect of Synbiotic on Glycemic Profile and Sex Hormones in Overweight and Obese Breast Cancer Survivors Following a Weight-Loss Diet: A Randomized, Triple-Blind, Controlled Trial Publisher Pubmed



Raji Lahiji M1 ; Najafi S2 ; Janani L3 ; Yazdani B4 ; Razmpoosh E5, 6 ; Zarrati M1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Nutrition, School of Public Health, Iran University of Medical Sciences, Tehran, Iran
  2. 2. Breast Disease Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran
  3. 3. Department of Biostatistics, School of Public Health, Iran University of Medical Sciences, Tehran, Iran
  4. 4. Department of Microbiology, School of Biology Sciences, Islamic Azad University, Tehran, Iran
  5. 5. Quality of Life Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran
  6. 6. Nutrition and Food Security Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran

Source: Clinical Nutrition Published:2021


Abstract

Background: The investigation was designed to assess the effects of synbiotic supplementation on glycemic profile, insulin-like growth factor-1 (IGF-1) and sex hormones in overweight and obese postmenopausal breast cancer survivors (BCSs) who had hormone-receptor-positive breast cancer. Methods: This randomized, triple-blind, placebo-controlled trial was conducted on 76 overweight and obese BCSs aged 57.43 (5.82) years. All participants were given a specified low calorie diet and were randomly assigned into two groups to intake 109 CFU/day of synbiotic supplement (n = 38) or placebo (n = 38) for 8 weeks. Body composition, physical activity, glycemic profile, IGF-1, estradiol, testosterone and dehydroepiandrosterone sulfate (DHEA-S) were measured at baseline and after 8 weeks. Results: A significant reduction in serum insulin (median change (Q1, Q3) from baseline of −1.05 (−2.36, 0.32) μIU/mL; P = 0.006) and insulin resistance (HOMA-IR) (mean change (SD) from baseline of −4.0 (0.9); P = 0.007) were seen over the 8 weeks in the synbiotic group. However, no significant changes were observed in serum insulin, fasting plasma glucose, HbA1c, HOMA-IR, IGF-1, estradiol, testosterone, DHEA-S and sex hormone binding globulin between-groups at the end of the intervention. Conclusions: Overall, as the 8-week synbiotic consumption compared with placebo had insignificant-reducing effects on glycemic profile, IGF-1 and sex hormones among overweight and obese postmenopausal BCSs, synbiotics may exert considerable beneficial consequences, which need to be further assessed in future clinical trials. Trial registration: IRCT, IRCT2015090223861N1. Registered 02 February 2017, http://www.irct.ir: IRCT2015090223861N1. © 2020 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism
2. Probiotics for Prophylaxis and Management of Breast Cancer: Preclinical and Clinical Evidence, Probiotic Research in Therapeutics: Volume 1: Applications in Cancers and Immunological Diseases (2020)
Experts (# of related papers)
Other Related Docs
24. Anti-Tumor Activities of Probiotics in Cervical Cancer, Journal of Ovarian Research (2020)